Abstract:Background: Previously known as the anti-rejection drug, then famous for its efficacy on many mTOR-regulated diseases, sirolimus is now reported as the drug to reverse the process of many age-related diseases, rejuvenate immunity, and extend life span. However, its long-term safety profile for all-age groups is still a concern.Methods: Data were from two 10-year prospective cohort studies (ChiCTR-OOB-15006535,NCT031938), in which patients were diagnosed with tuberous sclerosis and/or lymphangioleiomyomatosis. Indicators on growth, hematopoietic, liver and renal function, and blood lipid were all primary outcomes. GLM analysis and Chi-square test were used to reveal their changes between the baseline and five follow-up periods (< 6 months, 6 to < 12 months, 1 to < 2 years, 2 to < 4 years, and 4-to-10 years)). Four models with cross-validation were constructed for prediction. Descriptive adverse events and the change of regimens were also recorded (secondary outcomes). Findings: 1738 patients aging from 5 days to 69 years were included. The median follow-up period was 25 (12-43) months, and 380 patients were followed for more than four years. Z scores of height, weight, and BMI increased significantly throughout the follow-up (baseline versus 4-to-10-year follow-up: 0·24 vs 0·69, 0·25 vs 0·56, 0·14 vs 0·29). The dose of sirolimus was the only factor related to all the changes. No negative effects on hematopoietic, liver, and renal function were observed throughout the follow-up. On the contrary, the long-term use of sirolimus showed beneficial effects. The increase of blood lipids was mainly in the first six months. Stomatitis was the most common adverse event (920/1738, 52·9% ), and 48·5% of adult females were with menstrual disorders. The economic burden was the main reason for discontinuing therapy.Interpretation: For the first time, we observed the increase in height and weight brought by sirolimus. Also, the length of follow-up was associated with different safety profiles. Some beneficial effects were observed in a longer follow-up.Clinical Trial Registration Details: The pediatric patients in this study are from the "Efficacy and Safety of Sirolimus in Pediatric Patients with Tuberous Sclerosis (ESOSIPT)" study (Chinese Clinical Trial Registration, http://www.chictr.org.cn, No. ChiCTR-OOB-15006535). The adult patients re from "A National Registry on Chinese Patients with Lymphangioleiomyomatosis" (ClinicalTrials.gov, No. NCT03193892).Funding Information: This work was supported by grants from the National Key Research and Development Program of China (No. 2016YFC1000707,No.2016YFC0901502) and the National Natural Science Foundation of China (No. 81471329).Declaration of Interests: The authors have no conflicts of interest relevant tothis article to disclose.Ethics Approval Statement: The Ethics Committee of Chinese PLA General Hospital approved the pediatric study (No. S2013-028-01). The Ethics Committee of Peking Union Medical College Hospital (PUMCH) approved the adult study(JS-1323).

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma

Initial Dose Recommendation for Sirolimus in Paediatric Kaposiform Haemangioendothelioma Patients Based on Population Pharmacokinetics and Pharmacogenomics

Initial Dosage Recommendation for Sirolimus in Children With Tuberous Sclerosis Complex.

Initial Sirolimus Dosage Recommendations for Pediatric Patients with PIK3CD Mutation-Related Immunodeficiency Disease

Safety Profile of Sirolimus in All Age Groups: A Pooled Analysis of Two 10-Year Cohort Studies Comprising 1738 Patients With Tuberous Sclerosis and/or Lymphangioleiomyomatosis

Population pharmacokinetic analysis of sirolimus in Japanese pediatric and adult subjects receiving tablet or granule formulations

ABCB1 Haplotype Influences the Sirolimus Dose Requirements in Chinese Renal Transplant Recipients.

Therapeutic Drug Monitoring for Sirolimus in Children with Vascular Anomalies: What Can We Learn from a Retrospective Study

Population Pharmacokinetic Characteristics of Sirolimus in Healthy Chinese Subjects and Renal Transplant Patients

Population Pharmacokinetics Model and Initial Dose Optimization of Tacrolimus in Children and Adolescents with Lupus Nephritis Based on Real-World Data

Population Pharmacokinetics and Initial Dose Optimization of Tacrolimus in Children with Severe Combined Immunodeficiency Undergoing Hematopoietic Stem Cell Transplantation

Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis

A prospective multicenter study of sirolimus for complicated vascular anomalies

Experience in the Treatment of Lymphatic Vascular Malformations with Sirolimus, A Prospective Cohort Study in a Tertiary Hospital

Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients

Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the <i>CYP3A5</i> polymorphism and coadministration with Wuzhi capsule

Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics.

Efficacy of Sirolimus in a 17-Month Old Patient with Primary Intestinal Lymphangiectasia

Initial Dosage Optimization of Tacrolimus in Chinese Pediatric Patients Undergoing Kidney Transplantation Based on Population Pharmacokinetics and Pharmacogenetics

Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial

Healthcare utilization in patients with head and neck lymphatic malformations with the introduction of sirolimus